In a candid conversation from Boston, Elias Zerhouni, ex-NIH director and OPKO Health VP, charts India’s remarkable journey in pharmaceuticals—from generic powerhouse to innovation leader. This evolution, driven by vaccines and clinical prowess, signals a new era for the sector.
US-India health ties have strengthened exponentially, moving past manufacturing to collaborative R&D. Zerhouni spotlighted firms like Lupin and Sun Pharma, whose global footprints underscore India’s shift in perception. ‘India is no longer just a factory; it’s an innovation destination,’ he declared.
The country’s API and generic drug supremacy sustains world supplies, but vaccine capabilities, epitomized by Serum Institute, have been game-changers. ‘Global vaccination would falter without India’s contributions,’ Zerhouni asserted.
He lauded ‘frugal innovation’ as India’s secret weapon—high-impact solutions at low costs, embodying a commitment to inclusivity.
The pandemic revealed supply chain frailties, prompting a global reevaluation of preparedness. In democracies like India and the US, private enterprise leads the charge, propelled by mutual interests rather than mandates.
Zerhouni shared anecdotes of bureaucratic snags, including grant delays discussed with Manmohan Singh, highlighting shared democratic challenges. India’s clinical trial ecosystem is maturing, demanding strong infrastructure.
De-risking from China funnels investments to India in biotech and medtech. Contrasting US pricing woes with India’s access-driven model, he noted AI’s role in enhancing research efficiency without fully supplanting human ingenuity.
Biotech’s future is multipolar, with India at the forefront. Zerhouni concluded optimistically: ‘The origin of breakthroughs matters less than their impact on lives.’
